The U.S. Food and Drug Administration (FDA) has granted INS018_055 orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF), the therapy’s developer Insilico Medicine, announced. Insilico is expecting to initiate a global Phase 2 clinical trial testing INS018_055 in people with IPF later this year. Orphan drug…
Dosing has begun in a clinical trial evaluating ARO-MMP7, Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy for idiopathic pulmonary fibrosis (IPF). Expecting to enroll up to 56 healthy volunteers and 21 adults with IPF, the Phase 1/2a trial (NCT05537025) — dubbed AROMMP7-1001 — will evaluate the therapy’s…
Strados Labs is teaming up with Boehringer Ingelheim to conduct a pilot study leveraging its RESP Biosensor, a first-of-its-kind device designed to remotely monitor key changes in lung sounds, cough, and other respiratory issues in people with idiopathic pulmonary fibrosis (IPF) and other lung disorders. In Boehringer…
The highest tested dose of bexotegrast, an anti-fibrotic treatment candidate from Pliant Therapeutics, was found to best — and safely — improve lung function in people with idiopathic pulmonary fibrosis (IPF), outperforming all lower doses in a Phase 2a trial. Three-month data from the INTEGRIS-IPF trial (NCT04396756)…
The Pulmonary Fibrosis Foundation (PFF) is set to present the 13th edition of “Broadway Belts for PFF!” — an annual glitzy affair that has become the nonprofit’s single-largest fundraiser — on March 6. The gala, which also seeks to heighten awareness of pulmonary fibrosis (PF), will take place…
KIN001, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF), was more effective than Esbriet (pirfenidone) at easing lung fibrosis in a mouse model of the disease, its developer, Kinarus Therapeutics, reported. When KIN001 was given with Esbriet, an approved treatment, the reduction in fibrosis was even greater than…
The Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis (PF) has enrolled its last patient. Recruitment finished sooner than anticipated, according to INOpulse developer Bellerophon Therapeutics. Top-line results are expected later this year and it’s hoped they will support efforts on…
A protein called DACT2 alleviated signs of lung scarring in mouse models of idiopathic pulmonary fibrosis (IPF), researchers reported. In tests in cells, DACT2 was found to work by suppressing glycolysis, an energy-producing metabolic process that is overactive in myofibroblasts, the cells involved in excess scar tissue formation in IPF.
A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian is working to develop a first-in-class group of small molecules that would inhibit a protein called transglutaminase 2 (TG2), which plays a key role in fibrosis, or tissue scarring. Preclinical…
A Phase 2b clinical trial testing NP-120 (ifenprodil) as a treatment for chronic cough is expected to begin later this year, according to the therapy’s developer, Algernon Pharmaceuticals. But plans for a Phase 2b study of NP-120 in people with idiopathic pulmonary fibrosis (IPF) are postponed “until…
Get regular updates to your inbox.
